Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Septic Shock Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Septic Shock Overview | 10 | 1 |
| Pipeline Products for Septic Shock Comparative Analysis | 11 | 1 |
| Septic Shock Therapeutics under Development by Companies | 12 | 2 |
| Septic Shock Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Septic Shock Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Septic Shock Products under Development by Companies | 19 | 1 |
| Septic Shock Products under Investigation by Universities/Institutes | 20 | 1 |
| Septic Shock Companies Involved in Therapeutics Development | 21 | 16 |
| Adrenomed AG | 21 | 1 |
| Ferring International Center S.A. | 22 | 1 |
| Huons Co., Ltd. | 23 | 1 |
| InflaRx GmbH | 24 | 1 |
| Inotrem S.A. | 25 | 1 |
| Lixte Biotechnology Holdings, Inc. | 26 | 1 |
| Noxxon Pharma AG | 27 | 1 |
| Octapharma AG | 28 | 1 |
| Orion Oyj | 29 | 1 |
| Peptinov SAS | 30 | 1 |
| Pharmazz, Inc. | 31 | 1 |
| Spider Biotech | 32 | 1 |
| Takeda Pharmaceutical Company Limited | 33 | 1 |
| Therashock, LLC | 34 | 1 |
| ViiV Healthcare Limited | 35 | 1 |
| XImmune AB | 36 | 1 |
| Septic Shock Therapeutics Assessment | 37 | 9 |
| Assessment by Monotherapy Products | 37 | 1 |
| Assessment by Target | 38 | 2 |
| Assessment by Mechanism of Action | 40 | 2 |
| Assessment by Route of Administration | 42 | 2 |
| Assessment by Molecule Type | 44 | 2 |
| Drug Profiles | 46 | 37 |
| 3K3A-APC Drug Profile | 46 | 2 |
| adrecizumab Drug Profile | 48 | 1 |
| AM-12 Drug Profile | 49 | 1 |
| Aspidasept Drug Profile | 50 | 1 |
| BC-1215 Drug Profile | 51 | 1 |
| BMS-936559 Drug Profile | 52 | 2 |
| BTZO-2 Drug Profile | 54 | 1 |
| Drug for Sepsis and Septic Shock Drug Profile | 55 | 1 |
| HBN-1 Drug Profile | 56 | 1 |
| HBN-3 Drug Profile | 57 | 1 |
| HBN-4 Drug Profile | 58 | 1 |
| HU-003 Drug Profile | 59 | 1 |
| IFX-1 Drug Profile | 60 | 2 |
| L-257 Drug Profile | 62 | 1 |
| LB-100 Drug Profile | 63 | 2 |
| levosimendan Drug Profile | 65 | 4 |
| M-6229 Drug Profile | 69 | 1 |
| Motrem Drug Profile | 70 | 1 |
| NOXD-21 Drug Profile | 71 | 1 |
| PMZ-2010 Drug Profile | 72 | 1 |
| pooled plasma (human) Drug Profile | 73 | 1 |
| Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock Drug Profile | 74 | 1 |
| R-190 Drug Profile | 75 | 2 |
| SB-056 Drug Profile | 77 | 1 |
| selepressin Drug Profile | 78 | 1 |
| Small Molecule to Inhibit TNF-Alpha for Septic Shock Drug Profile | 79 | 1 |
| SP-14 Drug Profile | 80 | 1 |
| SP-9 Drug Profile | 81 | 1 |
| Synthetic Peptides for Inflammation and Infectious Disorders Drug Profile | 82 | 1 |
| Septic Shock Dormant Projects | 83 | 2 |
| Septic Shock Discontinued Products | 85 | 1 |
| Septic Shock Product Development Milestones | 86 | 5 |
| Featured News &Press Releases | 86 | 1 |
| Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock | 86 | 1 |
| Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery | 86 | 1 |
| Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody | 87 | 1 |
| Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan | 88 | 1 |
| Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients | 89 | 1 |
| Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock | 90 | 1 |
| Appendix | 91 | 2 |
| Methodology | 91 | 1 |
| Coverage | 91 | 1 |
| Secondary Research | 91 | 1 |
| Primary Research | 91 | 1 |
| Expert Panel Validation | 91 | 1 |
| Contact Us | 91 | 1 |
| Disclaimer | 92 | 1 |